BioCentury
ARTICLE | Clinical News

Prurisol abacavir acetate: Phase II ongoing

March 7, 2016 8:00 AM UTC

Cellceutix completed dosing in a double-blind, placebo-controlled, U.S. Phase II trial evaluating oral Prurisol for 84 days in 115 patients with mild to moderate chronic plaque psoriasis. Prurisol was...